Eagle Pharmaceuticals Inc. (EGRX) Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

June 13, 2022

Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint
– Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection
– BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year1 addressable market and projected annual peak sales of $2752 million in the U.S.
– Expected to be earnings accretive by 2024
WOODCLIFF LAKE, N.J., June 09, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced it has completed the acquisition of the entire …

Read the source article at Financial Research & Reports Finder
2022-06-09 15:32:00

Share This Story!